Premium
Can the reverse transcriptase‐polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen improve staging and predict biochemical recurrence?
Author(s) -
Adsan Ö.,
Cecchini M.G.,
Bisoffi M.,
Wetterwald A.,
Klima I.,
Danuser H.J.,
Studer U.E.,
Thalmann G.N.
Publication year - 2002
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1046/j.1464-410x.2002.02972.x
Subject(s) - prostatectomy , prostate cancer , prostate specific antigen , medicine , glutamate carboxypeptidase ii , antigen , polymerase chain reaction , prostate , urology , real time polymerase chain reaction , reverse transcription polymerase chain reaction , reverse transcriptase , biochemical recurrence , pathology , cancer , gene , biology , immunology , messenger rna , biochemistry
Objective To evaluate the perioperative gene‐specific primed nested reverse transcription‐polymerase chain reaction (RT‐PCR) for prostate‐specific antigen (PSA) and prostate‐specific membrane antigen (PSMA) for staging patients undergoing radical prostatectomy and predicting biochemical recurrence. Patients and methods In 80 consecutive patients undergoing radical prostatectomy for prostate cancer, blood samples were drawn before, during and 1 and 7 days after removing the prostate. After buffy coat and mRNA extraction, gene‐specific primed nested RT‐PCR was performed for PSA, PSMA and glyceraldehyde‐3‐phosphate dehydrogenase mRNA, and Southern blot analysis of the PCR reaction. Results The sensitivity of gene‐specific RT‐PCR to detect tumour cells was comparable with random primed RT‐PCR. In the 80 patients the stage distribution was pT1 in two (2.5%), pT2 in 30 (37.5%) and ≥ pT3 in 48 (60%); the nodal status was pN0 in 57 (71%), pN1 in 11 (14%) and pN2 in 12 (15%). The gene‐specific RT‐PCR reaction for PSA and PSMA was positive in no patients with pT1, 11 (37%) with pT2 and 23 (48%) with stage ≥ pT3 disease. The result for PSA was positive in 12 (52%) and for PSMA in 11 (48%) of those with positive nodal status. Neither gene‐specific RT‐PCR for PSA or PSMA was able to predict organ‐confined disease (P > 0.5). After a median (range) follow‐up of 37 (11–67) months a biochemical recurrence was predicted in 65% of patients by preoperative RT‐PCR for both PSA and PSMA, with a sensitivity, specificity, positive and negative predictive value of 58%, 80%, 87% and 47%, respectively; the assay after surgery predicted a recurrence in 73%, with respective values of 68%, 84%, 84% and 57%. Conclusions Gene‐specific primed nested RT‐PCR for PSA and PSMA is a sensitive and simple assay; it might add substantial information for tumour staging in individual patients. RT‐PCR before surgery allows the prediction of recurrence in 65% of cases and after surgery in 73%.